Source: Eur Respir J 2014; 43: 602-609



Rating:

Share or cite this content

Citations should be made in the following way:
Vorselaars Adriane D.M., Verwoerd Anouk, van Moorsel Coline H.M., Keijsers Ruth G.M., Rijkers Ger T., Grutters Jan C.. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur Respir J 2014; 43: 602-609

Member's Comments

No comment yet.

Related content which might interest you: Long-term treatment with infliximab in patients with sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 ABPA relapse after discontinuation of omalizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Relapse after discontinuation of infliximab in sarcoidosis patients can be predicted by PET-scan and sIL-2R Source: Annual Congress 2013 –Sarcoidosis Year: 2013 Efficacy and toxicity of azathioprine plus corticosteroids in 32 patients with chronic persistent sarcoidosis Source: Eur Respir J 2004; 24: Suppl. 48, 712s Year: 2004 Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment Source: Eur Respir J 2002; 20: Suppl. 38, 245s Year: 2002 Early recurrent exacerbation and exacerbation therapy Source: Eur Respir J 2006; 28: Suppl. 50, 841s Year: 2006 Sarcoidosis relapses in corticosteroid treated patients Source: Annual Congress 2012 - Novelties in clinical management of thoracic diseases: from diaphragm to pleura Year: 2012 Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia Source: Eur Respir J 2015; 45: 1624-1631 Year: 2015 Effect of ABPA treatment in severe asthma patients with acute and relapsed disease Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 High-doses glucocorticosteroid treatment in sarcoidosis patients Source: Eur Respir J 2007; 30: Suppl. 51, 118s Year: 2007 Safety of corticosteroid therapy in patients with pulmonary sarcoidosis Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017 Rituximab in the treatment of refractory pulmonary sarcoidosis Source: Eur Respir J 2014; 43: 1525-1528 Year: 2014 Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma Source: Eur Respir J, 55 (5) 1902259; 10.1183/13993003.02259-2019 Year: 2020 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab Source: International Congress 2016 – Sarcoidosis Year: 2016 The efficacy of omalizumab in severe in asthma after treatment withdrawal Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis Source: ERJ Open Res, 3 (3) 00016-2017; 10.1183/23120541.00016-2017 Year: 2017 Patients‘ reasons for early discontinuation of inhaled corticosteroids and their disease control Source: Eur Respir J 2007; 30: Suppl. 51, 285s Year: 2007 Effect of infliximab on lung function and well-being in patients with refractory sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 Effects of infliximab on systemic features in patients with COPD suffering from cachexia Source: Eur Respir J 2006; 28: Suppl. 50, 105s Year: 2006